
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc is experiencing significant growth, as evidenced by a 105% increase in fiscal 3Q26 revenue to $2.2 million and the successful expansion of its international distribution footprint to 40 countries. The company's innovative Nitric Oxide Generator and Delivery System has demonstrated strong market traction, underscored by its first sales to a VA Medical Center, which could enhance its platform credibility. Furthermore, the encouraging preliminary data from the Phase 1 trials of its UNO therapy suggests potential for a differentiated immunotherapeutic approach and reinforces investor confidence in the company’s growth trajectory within the respiratory and oncology sectors.
Bears say
Beyond Air Inc. is repositioning its UNO system from being viewed as a standalone ablation device to an adjunctive immunotherapy tool, indicating a shift in strategic focus that may complicate its marketing and adoption potential. This change suggests potential challenges in gaining regulatory approval and achieving commercial success, particularly in the competitive landscape of immunotherapy. Additionally, the company's dependence on successful integration with existing treatments, such as anti-PD-1 therapy, raises concerns about its long-term revenue prospects and market viability.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares